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ABSTRACT 
Neonatal infections are estimated to account for a quarter of the 2·8 million annual neonatal deaths, as well 
as approximately 3% of all DALYs. Despite this burden, data are limited on incidence, aetiology and outcomes, 
particularly regarding impairment. We aimed to develop guidelines for improved scientific reporting of 
observational and interventional neonatal infection studies, to increase comparability and to strengthen 
research in this area. This statement, Strengthening the Reporting of Observational Studies in Epidemiology 
for Newborn Infection (STROBE-NI) is an extension of the Strengthening the Reporting of Observational 
Studies in Epidemiology (STROBE) checklist. STROBE-NI was developed following systematic reviews of 
published literature (1996-2015), compilation of over 130 potential reporting recommendations, and 
circulation of a survey to relevant professionals worldwide, eliciting responses from 147 professionals from 
37 countries. An international consensus meeting of 18 participants (with expertise in infectious diseases, 
neonatology, microbiology, epidemiology and statistics) identified priority recommendations for reporting, 
additional to the STROBE statement. Implementation of these STROBE-NI recommendations, and linked 
checklist, aims to improve scientific reporting of neonatal infection studies, increasing data utility and 
allowing meta-analyses and pathogen-specific burden estimates to inform global policy and new 
interventions, including maternal vaccines.  
 
Words: 188 
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Strengthening the Reporting of Observational Studies in Epidemiology for Newborn 
Infection (STROBE-NI): An extension of the STROBE statement for neonatal infection 
research 
 
Background  
Progress in improving child survival has been one of the greatest successes in international development.1 
However, there is an unfinished agenda,2 since the mortality reduction has been slowest for neonates. 
Almost half (44%) of all child deaths now occur in the neonatal period (0-27 days),3 with a substantial burden 
of mortality in the first few days after birth.4 The “Every Newborn Action Plan” sets out a United Nations led 
platform, endorsed by all countries, to end preventable neonatal deaths, but requires data to implement and 
inform innovation.2,5  
 
Estimates by the World Health Organisation (WHO), for 195 countries, suggest that infection accounts for 
around 680 000 deaths – a quarter of all neonatal deaths annually;6 and half of all neonatal deaths in high 
neonatal mortality settings.2 The closely linked 2·6 million annual stillbirths have an as yet poorly quantified 
infection burden.7 Significant neurodevelopmental impairment affects approximately a quarter of neonates 
following meningitis, but impairment data are very limited worldwide, particularly for common infection 
syndromes such as sepsis and pneumonia.8,9       
 
There are an estimated 6·9 million neonates with possible serious bacterial infection (pSBI) annually in Sub-
Saharan Africa, South Asia and Latin America.8 Approximately 84% of neonatal deaths attributed to infections 
could be averted by increasing coverage of prevention and access to treatment, yet currently the gap is high, 
especially in the poorest countries.10 Recent large clinical trials have assessed the safety and efficacy of 
improving access to treatment through outpatient care, in cases where referral is not possible.11–13  
Aetiology-specific data for neonatal infections are limited, and challenging to combine. Hospital-based 
studies suggest that Staphylococcus aureus, Escherichia coli, Klebsiella species and group B Streptococci (GBS) 
may be the most common pathogens globally.14 As yet there are no community-based aetiological studies 
from Africa, and few from South Asia, which together carry over 75% of the burden. Hence, there is an urgent 
need to improve data on incidence (especially in the first days following birth), aetiology (bacterial, viral and 
fungal), antimicrobial sensitivity, and outcomes. These data are essential to understand the burden and risk 
factors, refine treatment algorithms, support potential interventions (eg. maternal vaccines for respiratory 
syncytial virus and Group B Streptococcus),15–17 and mitigate antimicrobial resistance, which threatens 
current treatment strategies.18–20 
Recording, reporting and interpreting neonatal infection data poses specific challenges. More than 95% of 
neonatal deaths occur in countries without adequate birth and death certification to capture cause-specific 
mortality,2,6 let alone pathogen-specific surveillance. Systematic clinical assessment, with investigations 
providing microbiological data, are also limited.8 Most available neonatal infection data are from tertiary 
referral hospitals, with recruitment bias, by missing those not accessing higher levels of care, or any care.21 
In population-based studies, which are extremely few in high burden settings,22–24 even if women are 
recruited in pregnancy, the challenge remains that many newborns die within hours of birth before being 
assessed; meaning counting, investigations and treatment are missed.25 In a population-based Bangladeshi 
cohort, 62% of neonates who died were never clinically assessed, with 59% of deaths occurring within 48 
hours of birth.22 Even when cases are captured in the numerator and denominator, case definitions are often 
inconsistent. Diagnosis is usually based on clinical expertise, or in settings with fewer health workers, on 
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simplified clinical algorithms designed to be highly sensitive. For example, the most commonly used WHO 
young infant pSBI algorithm is very sensitive (85%) and fairly specific (75%). 26–28 Additionally, unlike 
childhood infections, gestational age has a major effect on incidence, aetiology and outcomes of neonatal 
infections. Neonates of 25 and 35 week’s gestation are both preterm, yet differentiation between the two is 
often missing in reported data, which is crucial for interpretation. 
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)29 and Consolidated 
Standards of Reporting Trials (CONSORT)30 statements were developed to improve scientific reporting. 
Several extensions of these statements have been published with additional recommendations for 
specialised fields of research, for example, the Strengthening the Reporting of Molecular Epidemiology for 
Infectious Diseases (STROME-ID)31 and the Outbreak Reports and Intervention Studies of Nosocomial 
Infection (ORION)32 statement. These extensions build on the principles of STROBE and CONSORT but 
explicitly address additional, problematic methods or settings. There are reporting guidelines under 
development which are specific to child health trials (SPIRIT-C; CONSORT-C),33 and for systematic reviews 
and meta-analyses (PRISMA-C; PRISMA-PC).34 This paper aims to address the specific challenges in reporting 
neonatal infections, using the STROBE29 model. If these recommendations are applied by upcoming 
epidemiological and interventional studies on neonatal infections, the value of new data will increase, 
avoiding “research waste”.35 
Aims of STROBE-NI 
The purpose of these guidelines is to promote transparency, clarity and comparability of scientific reporting, 
specifically for neonatal infection research. We focus on observational studies (although many elements will 
be true for other study designs), and include detailed consideration of aetiological (bacterial, viral and fungal) 
data. Through improved reporting, we aim to facilitate reliable comparison of emerging newborn infection 
data across settings worldwide, and the synthesis of robust evidence to inform public health interventions. 
Our objectives were to assess current reporting components for neonatal infection in the literature, to list all 
potential reporting items, and to use an online survey and expert consensus process to develop the 
‘Strengthening Reporting of Observational Studies in Epidemiology for Newborn Infection (STROBE-NI)’ 
checklist. The STROBE-NI checklist is intended to guide authors, reviewers, publishers and funders of 
neonatal infection studies. We focussed on parameters that are not included in STROBE, or other extensions. 
  
Development of the STROBE-NI checklist   
The STROBE-NI checklist was developed using recommended methods.36 The participants, processes and 
outputs are illustrated in Figure 1. Literature searches were undertaken to identify highly cited neonatal 
infection publications from different regions worldwide (1996-2015), and more recent (2011-2015) articles 
from high impact journals (see supplementary material for literature search criteria). Additional searches 
were carried out for reporting guidelines relevant to neonatal infections.  
 
Through these reviews we identified a list of 133 reporting items, which was developed into an online survey 
(supplementary material). Respondents were asked to comment and/or rate the importance of each item in 
the list by selecting either ‘unnecessary’, ‘sometimes useful’, ‘important for most studies’, or ‘essential for 
all studies’. Participants were also asked to identify definitions and classifications requiring discussion and 
clarification. The survey was disseminated to relevant investigator groups, corresponding authors of 
reviewed papers, and professional infectious disease and paediatrics networks worldwide (Figure 1). 147 
experts replied, from 37 countries, with more than 41% from low/middle income counties (supplementary 
material).  
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In June 2015, a group of 18 international, multi-disciplinary experts (epidemiologists, statisticians, 
microbiologists, paediatricians, neonatologists) met in London to examine the literature reviews, potential 
reporting items and survey results and to draft the structure and content of the recommendations. 
Recommendations were aligned with STROBE items in one draft checklist, as a topic-specific 
implementation36 of the STROBE statement. The structural relationship between STROBE-NI and STROBE29 
recommendations is illustrated in Figure 2. 
 
The draft checklist was reviewed and revised by the expert group, disseminated to survey participants, and 
members of networks such as the Enhancing the Quality and Transparency of Health Research (EQUATOR) 
network, for further review and feedback, resulting in a final STROBE-NI Checklist (Table 1) 
 
STROBE-NI Standards 
The final STROBE-NI checklist is an extension of the 22 item STROBE list, with 28 additional parameters 
relating to neonatal infection. This includes a suggested flow diagram for both the recruitment and follow up 
of mothers and newborns, for which a template is provided in Figure 3. Below, we describe the additional 
recommendations for STROBE-NI that are not already outlined in detail in STROBE, or other extensions.  
 
Methods: Study design 
Clinical case definitions (STROBE-NI 4·1 – 4·4)  
The individual clinical signs used in clinical case definition algorithms should be detailed, (STROBE-NI 4·1), 
making clear whether case ascertainment was through physician diagnosis or a clinical algorithm (eg. Young 
Infants Clinical Signs Study Group algorithm for pSBI). Definitions of neonatal infection syndromes 
(pneumonia, meningitis and sepsis) are important for consistency and comparability, however, they cannot 
be distinguished on clinical grounds alone. Where authors are reporting case definitions of specific 
syndromes, microbiological and/or laboratory and/or radiological criteria for diagnosis should be stated 
(STROBE-NI 4·1), differentiating between probable and confirmed cases. For meningitis, the indications for 
lumbar puncture should be described (STROBE-NI 4·1). Case definitions should be aligned to international 
standards, when available and ideally be clinically validated.26 Clinical algorithms may introduce case 
ascertainment bias, and potential limitations of case definitions should be discussed.   
 
Authors should state the criteria used to differentiate between new infection episodes and relapses (STROBE-
NI 4·2). For example, new episodes may be considered when clinical signs develop more than 7 days after 
stopping treatment, versus a relapse, with reoccurrence of clinical signs within 7 days of stopping treatment. 
This is important for healthcare associated infections, and these should be explicitly differentiated from 
community-acquired infections, with reference to an international standard definition (STROBE-NI 4·3).37 
Where relevant, specific hospital acquired infections such as ventilator associated pneumonia and central 
line associated bloodstream infection should be defined, and presented separately.37 Reporting whether the 
observed cases were part of an outbreak (see ORION statement)32 is essential, and the definition used for 
outbreaks (STROBE-NI 4·4). 
 
Microbiological sampling (STROBE-NI 4·5) 
The microbiological sampling strategy for infections should be presented (STROBE-NI 4·5), such as samples 
being taken from all participants, or a subset meeting a case-definition (eg pSBI). This is important given that 
the positive and negative predictive values of tests differ according to the prevalence in those sampled. For 
instance if few cases of pSBI have lumbar punctures, then cases of meningitis may not be captured. Numbers 
from whom samples were taken, and sample type, should be provided, including sample volume ranges for 
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blood cultures, or minimum sample volume, as small volumes reduce sensitivity. It should be reported 
whether samples were taken prior to antimicrobial administration (which reduces sensitivity of testing) 
(STROBE-NI 4·5).  
 
Microbiological methods (STROBE-NI 4·6 – 4·8) 
Detailed reporting of laboratory methods is essential in order to assess implications and potential biases 
(STROBE-NI 4·6). To assess the extent of diagnostic investigation, a list of pathogens (or types of pathogen) 
being tested for, or likely to be identified by the methods used, should be available (including bacteria, viruses 
and fungi) (STROBE-NI 4·7). For diagnostic technologies using molecular methods, details of the assay should 
be given, describing any control samples used to determine clinical significance of detected organisms.38–40 
Antimicrobial susceptibility testing methodology should be reported according to an international standard 
(eg. Clinical and Laboratory Standards Institute) reporting the susceptibilities tested, and the criteria used to 
determine susceptibility to each antimicrobial (STROBE-NI 4·8). For molecular analyses, methods41 should be 
explained (eg. for whole genome sequencing, details of mapping to reference genomes and quality 
assessment of sequences). Further details are in STROME-ID.31 
 
Methods: Setting 
Context and denominator (STROBE-NI 5·1 – 5·2) 
Where possible, preterm, stillbirth, and neonatal mortality risks or rates at the study facility are helpful 
contextual information (STROBE-NI 5·1). This could be presented as the annual number of deaths, preterm 
births and stillbirths at the health facility, with live births (including the live birth definition used) or total 
births at the facility as the denominator.   
 
When considering infection acquisition, stratification into ‘inborn’ or ‘outborn’ is not specific enough to be 
helpful, as multiple pathways to healthcare presentation exist; ‘outborn’ may reflect births at home or at 
another facility, and ‘inborn’ does not differentiate between those admitted from birth, and those returning 
to the facility following discharge. Alternative categories are ‘admitted from birth at this facility’, ‘referred 
from another facility’ or ‘referred from home’ (STROBE-NI 5·2). If specifying place of birth as a variable, similar 
categories of ‘born at this facility’, ‘born at another facility’ or ‘born at home’ could be used.  
 
Community studies (STROBE-NI 5·3) 
Community-based studies should report the surveillance strategy, including whether active or passive, and 
the methods used for defining and enumerating the population. Passive surveillance may underestimate 
disease, especially where care seeking is low (varying from 10 to 100%),21 and an estimate of this should be 
made if possible.  For active surveillance, if clinical algorithms are used by community health workers visiting 
homes, this should be documented, including visitation schedules. Active surveillance increases case 
ascertainment, particularly on days when visits are made.42 In view of variation in adherence to referral, 
details on referral (including time from first presentation to treatment) are necessary, as well as loss to 
follow-up (STROBE-NI 5·3). This could be presented in a flow diagram (Figure 3).  
 
Facility based studies (STROBE-NI 5·4 – 5·6) 
Levels of neonatal and obstetric care differ greatly. The obstetric care available,43 including the percentage 
of births that occur in a facility (versus the community) and the incidence of operative delivery, should be 
described (STROBE-NI 5·4). Details about the level of neonatal care in place are essential, including availability 
of basic neonatal care (eg. resuscitation, breastfeeding practices) and if there is intensive neonatal care such 
as ventilation (eg. invasive, non-invasive, oxygen), indwelling catheters, intravenous fluids, staffing (eg. nurse 
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to patient ratio), non-microbiological investigations (eg. biochemistry, radiology) and treatment (eg. 
antimicrobials available) (STROBE-NI 5·5). Where relevant, specific clinical infection control measures in place 
(and level of adherence), may be important contextual information to understand potential routes of 
infection acquisition and transmission.  
 
The microbiology laboratory should be described, including location, facilities for different sample types and 
capacity for conventional and/or molecular microbiology. Laboratory quality control and quality assurance 
measures should be reported (STROBE-NI 5·6). 
 
Methods: Participants 
Neonatal age groups (STROBE-NI 6·1) 
The ‘neonatal’ period is defined as <28 days (i.e. day 0 to 27·99) from birth. For babies born before 37 weeks 
gestation, noting gestational age at birth is essential to allow age correction. Disaggregating neonatal data 
from infants and children is important due to differing risk factors, aetiologies and outcomes (STROBE-NI 
6·1).44 Timing is crucial for neonatal infections as incidence rates for pathogens, such as Group B 
Streptococcus, vary by day.45 The day of birth is best termed “day 0”, as used in demographic work and most 
epidemiological studies (STROBE-NI 6·1). Time limits vary as to when ‘day 0’ becomes ‘day 1’ (eg. at midnight, 
or 24h after birth), and the method used should be stated.4  
 
Methods: Variables 
Clinical significance of pathogens (STROBE-NI 7·1) 
Authors should be explicit about the clinical significance of the organisms detected. This may vary across 
settings (particularly organisms associated with indwelling devices, eg. coagulase negative staphylococci)46 
and the rationale for determining clinical significance should be stated, including control data, if available.38–
40 Publishing comprehensive lists of detected organisms, by sample type (eg. cerebrospinal fluid, blood), 
categorised as clinically significant, probably significant and clinically non-significant (the preferred term to 
“contaminant”) are encouraged (STROBE-NI 7·1); as criteria for clinical significance may change over time. 
 
Results: Participants 
Flow diagram (STROBE-NI 13·1) 
Figure 3 illustrates how the flow of eligibility, recruitment, sampling and diagnosis can be mapped in neonatal 
infection studies, including mothers and neonates (STROBE-NI 13·1).  
 
Results: Descriptive data (STROBE-NI 14·1 – 14·4) 
Maternal infections, and risk factors for infection, are important to report as maternal infections may result 
in vertical transmission and early onset neonatal infections, or stillbirth.47,48 Results of antenatal screening 
tests (eg. for GBS, syphilis, HIV) when done, and risk factors at delivery (eg. prolonged rupture of membranes 
(>18h) fever, maternal urinary tract infection) (STROBE-NI 14·1), are important for identifying high risk groups 
and informing interventions.49 
 
Neonatal characteristics, including sex, postnatal and gestational age categories (e.g. <28 weeks; 28 – <32 
weeks; 32 – <37 weeks; ≥37 weeks)50, birth weight categories (e.g. <=1500 grams; 1501-2500 grams;  >2500 
grams), place of birth (see above) and mode of feeding should be described, with ranges and medians stated 
for each numeric variable (STROBE-NI 14·2). Co-morbidities (eg. neonatal encephalopathy) should be 
reported, including any exclusion from analysis (STROBE-NI 14·2). Reporting of individual clinical signs is 
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encouraged (STROBE-NI 14·3),8 allowing comparison with other studies and may be helpful in refining 
diagnostic algorithms.2  
Details of treatment given before and after enrolment are important (STROBE-NI 14·4). Serum antimicrobial 
testing has shown that parents under-report antimicrobial administration;22 and results of testing are 
preferable to report. Use of intrapartum antibiotic prophylaxis and its indication (eg. maternal risk factors 
versus positive GBS screening)51 should be reported to inform interpretation of culture results (STROBE-NI 
14·4). 
 
Results: Outcome data 
Microbiological results (STROBE-NI 15·1 – 15·2) 
Microbiological results should be reported in the context of participants recruited, and the number and type 
of samples taken (STROBE-NI 15·1-2). For example, the number of those meeting clinical criteria for 
diagnostic lumbar puncture should be provided, as well as the cerebrospinal fluid results. The number and 
proportion of microbiologically proven clinical infections should be given, and incorporated within a flow 
diagram (Figure 3) (STROBE-NI 15·2).  
 
Reporting all organisms detected (eg. as an appendix), including those considered clinically non-significant, 
is helpful. For molecular assays in particular, reporting thresholds for detection and the organisms detected 
in control samples supports clinical case interpretation.38–40 Antimicrobial susceptibility data are essential to 
guide future antimicrobial policy development (STROBE-NI 15·1). It is helpful to provide raw antimicrobial 
susceptibility test result data (eg. minimum inhibitory concentrations), which can be analysed further in the 
future if international standards change.  
 
Timing of infection (STROBE-NI 15·3) 
Where categorisation into ‘early-onset’ (e.g. within 72 hours of birth) and ‘late-onset’ (e.g. after 72 hours of 
birth) disease is used, these terms should be clearly defined (STROBE-NI 15·3). Due to the changing 
aetiologies of neonatal disease, reporting infections by day, for the first week after birth (days 0-6) (STROBE-
NI 15·3) is more informative than dichotomous categories, and may improve understanding of early and late 
onset disease.45  
 
Mortality (STROBE-NI 15·4) and long-term outcomes  
Mortality and other serious clinical outcomes should be reported (STROBE-NI 15·4), ideally by day (Figure 3). 
Sample size permitting, stratifying mortality by potential risk factors including sex, birthweight categories, 
gestational age groups,50 infection syndromes, individual pathogens or antimicrobial resistance profiles, may 
highlight intervention opportunities for high risk groups.  
 
Where studies are reporting other long-term outcomes, such as neurological impairment, an international 
standard approach should be used, including the timing of follow up and assessment.  
 
Results: Main results 
Incidence (STROBE-NI 16·1) 
For incidence, the selection and source of the denominator should be explained (see above). For neonates it 
is usual to calculate incidence risk per 1000 live births (STROBE-NI 16·1), as the time period (28 days) is short. 
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Discussion: Limitations 
Bias (STROBE-NI 19·1) 
The first 12-48 hours after birth are critical, as the survival curve is steep,4 and infectious aetiologies differ 
later after birth. These aetiologies may be systematically underestimated if there is recruitment bias arising 
from lack of access to care, or death before accessing care (STROBE-NI 19·1).44 Identifying possible causes of 
recruitment and other biases in studies is therefore essential in interpreting findings.  
For all denominators used, authors should state the source (eg. hospital data or census / registration data), 
commenting on possible bias (STROBE-NI 19·1).  
 
Other information: Ethics (STROBE-NI 23·1) 
Because of ethical issues around recruitment, consent, and sampling in neonates, approaches taken must be 
reported, including processes for requesting consent from young mothers (minors) (STROBE-NI 23·1).52,53  
If the time frame for sample collection and obtaining consent is limited (eg. during delivery), a staged process 
of consent may be appropriate, to avoid exclusion of emergency cases (and reduce recruitment bias).54  
 
Implications of STROBE-NI 
The STROBE-NI checklist provides a tool for researchers, funders, reviewers and publishers to improve 
neonatal infection data, which have specific, previously unaddressed, requirements for scientific reporting. 
Building on the STROBE29 statement and its related extensions, the checklist primarily targets observational 
studies.29 However, STROBE-NI checklist items should also be considered for randomised controlled trials, 
alongside other guideline extensions.33,34 To our knowledge, there are no other reporting guidelines specific 
to neonatal health research.34 Whilst neonatal infections are a priority starting point, future re-iterations 
should also address other aspects of neonatal research, as well as maternal, and stillbirth outcomes. Only 
recommendations for reporting acute outcomes of infection were included in this checklist. However we 
recognise that other important long-term outcomes, such as neurological impairment, are increasingly being 
assessed, and are important to include.55 Reporting guidance for impairment outcomes after neonatal 
infection as well as other common neonatal complications, such as preterm birth,56 is an area for future 
development.  
 
The STROBE-NI checklist guides minimum standards for high quality reporting but is not exhaustive; and 
certain research objectives or contexts may necessitate other details. For instance, new technologies, such 
as molecular investigations,31,38 are likely to require additional descriptors.  
 
This list was designed to be applicable to a wide range of settings, including those with limited resources and 
a high neonatal infection burden. To achieve this, we sought inputs from around the world through experts, 
and our online survey, as well as systematic literature reviews.  
 
Uptake of the STROBE-NI checklist depends on dissemination through global research networks and meetings, 
and use by journals, funders and academics. Feedback and suggestions for improvement would be welcomed, 
as the STROBE-NI checklist will be updated periodically. Going forward, we intend to present ‘explanation 
and elaboration’ of this guidance (to build on that included in the supplementary material), develop abstract 
guidance for conference submissions, and evaluate the impact of STROBE-NI, as is recommended.36  
The STROBE-NI checklist has been developed at a critical point in time for emerging opportunities in neonatal 
infection research. It is a demonstration of a new commitment towards reducing the unacceptable burden 
of mortality and morbidity from neonatal infection, and more broadly, as part of the movement to end 
preventable maternal and newborn deaths, and stillbirths.5,57–59 
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Figure 3: Strengthening Reporting of Observational Studies in Epidemiology for Newborn Infection 
(STROBE-NI) recommended flow chart showing recruitment and participation in the study 
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Table 1:  Strengthening Reporting of Observational Studies in Epidemiology for Newborn Infection 
(STROBE-NI) Checklist: An extension of the STROBE statement for neonatal infection research29 
Section Item No.                                             Recommendation       
TITLE AND ABSTRACT 
  STROBE 
1(a) 
Indicate the study's design with a commonly used term in the title or abstract 
   STROBE 
1(b) 
Provide in the abstract an informative and balanced summary of what was done and what 
was found 
INTRODUCTION 
Background  
/ rationale 
STROBE 
2 
Explain the scientific background and rationale for the investigation being reported 
Objectives STROBE 
3 
State specific objectives, including any pre-specified hypotheses 
METHODS 
Study design STROBE 
4 
Present key elements of study design early in the paper 
  STROBE-NI 
4.1 
Clearly state case ascertainment methods (eg. physician diagnosis, clinical algorithm), 
documenting individual clinical signs used for diagnosis of possible serious bacterial 
infection. Give microbiological and/or laboratory and/or radiological criteria for other 
infectious syndromes (eg. meningitis, sepsis, pneumonia). Include indications for clinical 
investigations (eg. lumbar puncture) 
  STROBE-NI 
4.2 
Give criteria used to differentiate between new infection episodes and relapses  
  STROBE-NI 
4.3 
For facility-based studies, indicate if the study is of community and/or hospital acquired 
infections (HAI), defining HAI using an international standard and presenting specific HAI 
clinical syndromes separately 
  STROBE-NI 
4.4 
State whether this is an outbreak study, and if so define an outbreak, with reference to an 
international standard 
  STROBE-NI 
4.5 
Describe sampling strategy (eg. clinical indication vs. routine surveillance) and sampling 
details, (eg. minimum volumes; timing in relation to antimicrobial administration) 
  STROBE-NI 
4.6 
Describe conventional and/or molecular microbiological methods used, with details (eg. 
automation, enrichment steps), and the use of controls 
  STROBE-NI 
4.7 
List pathogens that are likely to be identified by microbiological methods used, and criteria 
used to determine clinical significance  
  STROBE-NI 
4.8 
Describe antimicrobial susceptibility tests and thresholds used, with reference to an 
international standard (eg. CLSI or EUCAST) 
Setting STROBE 
5 
Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
  STROBE-NI 
5.1 
Describe the study context in terms of incidence of neonatal mortality, stillbirth and preterm 
birth.  
 STROBE-NI 
5.2 
Describe the population included eg. facility live births, referrals from home, referrals from 
another facility 
  STROBE-NI 
5.3 
For community-based studies, describe care-seeking and adherence and time to referral 
  STROBE-NI 
5.4 
For facility-based studies, describe obstetric care (basic or comprehensive), including 
proportion of births by caesarean section. Report annual number of live births per facility 
and state proportion of births in the study area that occur in hospital (vs. community) 
  STROBE-NI 
5.5 
For facility-based studies, indicate if the facility is public or private, and give the number of 
health care staff and their training. Indicate the level of neonatal care available (eg. 
ventilatory support, indwelling catheters) and investigations available (eg. biochemistry, 
radiology). Report antimicrobial guidelines used for the empiric management of neonatal 
sepsis. 
 STROBE-NI 
5.6 
State the laboratory location and capacity to process different sample types, and give quality 
control and assurance measures in place. 
 18 
 
Participants STROBE 
6(a) 
Cohort study—Give the eligibility criteria, and the sources and methods of selection of 
participants. Describe methods of follow-up 
  Case-control study—Give the eligibility criteria, and the sources and methods of case 
ascertainment and control selection. Give the rationale for the choice of cases and controls 
  Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection 
of participants 
  STROBE 
6(b) 
Cohort study—For matched studies, give matching criteria and number of exposed and 
unexposed 
  Case-control study—For matched studies, give matching criteria and the number of controls 
per case 
  STROBE-NI 
6.1 
State age of participants (eg. 0-27 days defines neonates; 'day 0' as day of birth). 
Disaggregate neonatal data from that of older infants and from stillbirths 
Variables STROBE 
7 
Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
  STROBE-NI 
7.1 
State criteria used to define clinically significant organisms for each sample type 
Data sources 
measurement 
STROBE 
8 
For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
Bias STROBE 
9 
Describe any efforts to address potential sources of bias 
Study size STROBE 
10 
Explain how the study size was arrived at 
Quantitative 
variables 
STROBE 
11 
Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
Statistical 
methods 
STROBE 
12(a) 
Describe all statistical methods, including those used to control for confounding 
  STROBE 
12(b) 
Describe any methods used to examine subgroups and interactions 
  STROBE 
12(c) 
Explain how missing data were addressed 
  STROBE 
12(d) 
Cohort study—If applicable, explain how loss to follow-up was addressed 
  Case-control study—If applicable, explain how matching of cases and controls was addressed 
  Cross-sectional study—If applicable, describe analytical methods taking account of sampling 
strategy 
  STROBE 
12(e) 
Describe any sensitivity analyses 
RESULTS 
Participants STROBE 
13(a) 
Report numbers of individuals at each stage of study—eg. numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and 
analysed 
  STROBE 
13(b) 
Give reasons for non-participation at each stage 
  STROBE 
13(c) 
Consider use of a flow diagram 
  STROBE-NI 
13.1 
See Figure 3 for suggested components of a flow diagram for neonatal infections 
Descriptive 
data 
STROBE 
14(a) 
Give characteristics of study participants (eg. demographic, clinical, social) and information 
on exposures and potential confounders 
  STROBE-NI 
14.1 
Describe maternal infections (clinical or on screening, eg. GBS or HIV) or risk factors for 
infection (eg. PROM, peripartum fever).   
  STROBE-NI 
14.2 
Describe key neonatal characteristics, including sex, postnatal and gestational age categories 
(range and median), birth weight categories (range and median), birth place, feeding (breast 
milk or other) and comorbidities 
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  STROBE-NI 
14.3 
Report data on occurrence of individual signs (eg. fast breathing), according to case 
definitions 
  STROBE-NI 
14.4 
Give proportion of mothers and neonates with peripartum antibiotic exposure (+/- pre-
admission exposure for neonates). Report details of antimicrobials (or supportive care) given 
during the study 
  STROBE 
14(b) 
Indicate number of participants with missing data for each variable of interest 
  STROBE 
14(c) 
Cohort study—Summarise follow-up time (eg. average and total amount) 
Outcome data STROBE 
15 
Cohort study—Report numbers of outcome events or summary measures over time 
  Case-control study—Report numbers in each exposure category, or summary measures of 
exposure 
  Cross-sectional study—Report numbers of outcome events or summary measures 
  STROBE-NI 
15.1 
Report the number (+/- proportion) of samples microbiologically tested (including lumbar 
punctures for meningitis cases); the number (+/-proportion) that were positive (including 
thresholds for detection, where applicable); all isolates obtained (including clinically 
significant and non-significant); and antimicrobial susceptibilities of pathogens, where done. 
  STROBE-NI 
15.2 
Report number (+/- proportion) of babies with microbiologically proven infection (and 
number of infections per baby), and include this in the flow chart (see Figure 3). 
 STROBE-NI 
15.3 
Report infections by day, for days 0-6. State age categories, if used, defining ‘early-onset’ and 
‘late-onset’ infection (eg. <72 hours and ≥ 72 hours respectively).  
  STROBE-NI 
15.4 
Report deaths and any sub-analyses by risk groups  
Main results STROBE 
16(a) 
Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg. 95% confidence interval). Make clear which confounders were adjusted for and 
why they were included 
  STROBE 
16(b) 
Report category boundaries when continuous variables were categorized 
  STROBE 
16(c) 
If relevant, consider translating estimates of relative risk into absolute risk for a meaningful 
time period 
  STROBE-NI 
16.1 
For incidence, give risk per 1000 live births, or if alternative denominator used (eg. total 
births or bed days), define this clearly 
Other analyses STROBE 
17 
Report other analyses done—eg. analyses of subgroups and interactions, and sensitivity 
analyses 
DISCUSSION 
Key results STROBE 
18 
Summarise key results with reference to study objectives 
Limitations STROBE 
19 
Discuss limitations of the study, taking into account sources of potential bias or imprecision. 
Discuss both direction and magnitude of any potential bias 
 STROBE-NI 
19.1 
Discuss sources of recruitment bias, particularly regarding the period of time shortly after 
birth. State source of denominator data and discuss possible related biases 
Interpretation STROBE 
20 
Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
Generalisability STROBE 
21 
Discuss the generalisability (external validity) of the study results 
OTHER INFORMATION 
Funding STROBE 
22 
Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
Ethics STROBE-NI 
23.1 
Report any ethical considerations, including the recruitment of young mothers (minors), and 
the consent process for early recruitment of neonates after delivery. Provide details of 
research ethics approval. 
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SECTION 1: Literature Review and Preliminary List 
1.A. Search strategy and selection criteria for neonatal infection articles 
 
Search terms: 
[All Fields] neonat* OR newborn* OR newborn infant* OR young infant* AND 
[All Fields] infect* OR sepsis OR meningitis OR pneumonia OR tetanus OR omphalitis 
Inclusion criteria: 
- Papers presenting primary microbiological data on infections in neonates (0-27 days), including studies of 
infections in children who present separate neonatal data 
Exclusion criteria: 
- Studies with data only from very high risk neonatal populations (eg. very low birth weight, extremely premature) 
- Studies focussing on HIV, TB, syphilis, malaria or other congenital infections 
Search 1: Literature from seven Global Burden of Disease region 
 SCOPUS database (which gives citation data) 
 1996 to February 2015 (last search 27th February 2015) 
 Searches for literature with author affiliations to institutions in countries within each of seven Global Burden of 
Disease Regions1 and presenting primary data from a country in that region 
i. Central Europe, Eastern Europe, and Central Asia 
ii. Latin American and Caribbean 
iii. North Africa and Middle East 
iv. South Asia 
v. Southeast Asia, East Asia and Oceania 
vi. Sub-Saharan Africa 
vii. High income countries – Asia-Pacific, North America, Western Europe, Australasia, 
viii. Southern Latin America 
 All studies from each region ranked by number of citations per year 
 Three studies, from each region, with the highest number of citations per year selected for review 
Search 2: Recent literature from high impact infectious diseases and paediatric journals  
(excluding journals not publishing neonatal infection articles eg. Journal of the American Academy of Child & 
Adolescent Psychiatry) 
 Pubmed database 
 2011 to March 2015 (last search 15th March 15) 
 Highest impact infectious disease journals searched: 
i. Lancet Infectious Diseases 
ii. Clinical Infectious Diseases 
iii. Emerging Infectious Diseases  
iv. Journal of Infectious Diseases 
 Highest impact paediatric journals searched: 
i. Pediatrics 
ii. Archives of Pediatrics & Adolescent Medicine 
iii. Archives of Disease in Childhood – Fetal and Neonatal Edition 
iv. Journal of Pediatrics 
Reference: 
1 Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived 
with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the 
Global Burden of Disease Study 2013. Lancet 2015; 6736. DOI:10.1016/S0140-6736(15)60692-4.  
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1.B. Search results – papers selected for review  
Table 1: Neonatal infection literature from seven global regions 
Super-GBD 
 Region 
Title Country Authors Year Journal 
Citations 
 per year 
South Asia 
Population-Based Incidence and Etiology of Community-
Acquired Neonatal Bacteremia in Mirzapur, Bangladesh: An 
Observational Study 
Bangladesh 
Darmstadt G.L., Saha S.K., Choi Y., Arifeen S.E., Ahmed N.U., Bari S.,  
Rahman S.M., Mannan I., Crook D., Fatima K., Winch P.J., Seraji H.R., Begum 
N., Rahman N., Islam M., Rahman A., Black R.E., Santosham M., Sacks E., 
Baqui A.H. 
2009 
Journal of Infectious 
Diseases 
4.8 
Multidrug resistant neonatal sepsis in Peshawar, Pakistan Pakistan Rahman S., Hameed A., Roghani M.T., Ullah Z. 2002 
Archives of Disease in 
Childhood:  
Fetal and Neonatal Edition 
4.0 
Early onset neonatal sepsis India Chacko B., Sohi I. 2005 Indian Journal of Pediatrics 3.9 
Latin America & 
The Caribbean 
A 10-year prospective surveillance of nosocomial infections 
in neonatal intensive care units 
Brazil 
Couto R.C., Carvalho E.A.A., Pedrosa T.M.G., Pedroso E.R., Neto M.C., 
Biscione F.M. 
2007 
American Journal of 
Infection Control 
9.1 
Nosocomial infections in a neonatal intensive care unit: 
Incidence and risk factors 
Brazil Nagata E., Brito A.S.J., Matsuo T. 2002 
American Journal of 
Infection Control 
5.3 
Reduction in colonization and nosocomial infection by 
multiresistant bacteria in a neonatal unit after institution of 
educational measures and restriction in the use of 
cephalosporins 
Brazil Calil R., Marba S.T.M., von Nowakonski A., Tresoldi A.T. 2001 
American Journal of 
Infection Control 
4.1 
North Africa & 
The Middle East 
Neonatal nosocomial sepsis in a level-III NICU: Evaluation 
of the causative agents and antimicrobial susceptibilities 
Turkey Yalaz M., Cetin H., Akisu M., Aydemir S., Tunger A., Kultursay N. 2006 
Turkish Journal of 
Pediatrics 
3.3 
Changing spectrum of neonatal omphalitis Oman Sawardekar K.P. 2004 
Pediatric Infectious 
Disease Journal 
3.0 
A case control study of neonatal sepsis: Experience from 
Saudi Arabia 
Saudi Arabia Dawodu A., Al Umran K., Twum-Danso K. 1997 
Journal of Tropical 
Pediatrics 
1.4 
Nosocomial infection in a neonatal intensive care unit: A 
prospective study in Taiwan 
Taiwan Su B.-H., Hsieh H.-Y., Chiu H.-Y., Lin H.-C., Lin H.-C. 2007 
American Journal of 
Infection Control 
4.9 
 4 
Southeast Asia, 
East Asia & 
Oceania 
Neonatal enterovirus infections: Emphasis on risk factors of 
severe and fatal infections 
Taiwan 
Lin T.-Y., Kao H.-T., Hsieh S.-H., Huang Y.-C., Chiu C.-H., Chou Y.-H., Yang 
P.-H., Lin R.-I.,  
Tsao K.-C., Hsu K.-H., Chang L.-Y. 
2003 
Pediatric Infectious 
Disease Journal 
4.3 
Identification of febrile neonates unlikely to have bacterial 
infections 
Taiwan Chiu C.-H., Lin T.-Y., Bullard M.J. 1997 
Pediatric Infectious 
Disease Journal 
2.4 
Sub-Saharan  
Africa 
Viral etiology of severe pneumonia among Kenyan infants 
and children 
Kenya 
Berkley J.A., Munywoki P., Ngama M., Kazungu S., Abwao J., Bett A., 
Lassauniere R.,  
Kresfelder T., Cane P.A., Venter M., Scott J.A.G., Nokes D.J. 
2010 JAMA 21.4 
Predictors of positive blood culture and deaths among 
neonates with suspected neonatal sepsis in a tertiary 
hospital, Mwanza- Tanzania 
Tanzania Kayange N., Kamugisha E., Mwizamholya D.L., Jeremiah S., Mshana S.E. 2010 BMC Pediatrics 8.2 
Bacteremia in febrile Malawian children: Clinical and 
microbiologic features 
Malawi Walsh A.L., Phiri A.J., Graham S.M., Molyneux E.M., Molyneux M.E. 2000 
Pediatric Infectious 
Disease Journal 
7.4 
High Income 
Countries 
Bacterial meningitis in the United States in 1995 USA 
Schuchat A., Robinson K., Wenger J.D., Harrison L.H., Farley M., Reingold 
A.L.,  
Lefkowitz L., Perkins B.A. 
1997 
New England Journal of 
Medicine 
46.9 
Epidemiology of invasive group B streptococcal disease in 
the United States, 1999-2005 
USA 
Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., 
 Craig A.S., Schaffner W., Zansky S.M., Gershman K., Stefonek K.R., Albanese 
B.A., Zell E.R., Schuchat A., Schrag S.J. 
2008 
JAMA - Journal of the 
American  
Medical Association 
41.0 
Group B streptococcal disease in the era of intrapartum 
antibiotic prophylaxis 
USA 
Schrag S.J., Zywicki S., Farley M.M., Reingold A.L., Harrison L.H., Lefkowitz 
L.B.,  
Hadler J.L., Danila R., Cieslak P.R., Schuchat A. 
2000 
New England Journal of 
Medicine 
39.9 
Central Europe, 
Eastern Europe 
& Central Asia 
Use of an alcohol-based hand rub and quality improvement 
interventions to improve hand hygiene in a Russian neonatal 
intensive care unit 
Russia 
Brown S.M., Lubimova A.V., Khrustalyeva N.M., Shulaeva S.V., Tekhova I., 
Zueva L.P.,  
Goldmann D., O'Rourke E.J. 
2003 
Infection Control and 
Hospital  
Epidemiology 
4.9 
Etiology of neonatal blood stream infections in Tbilisi, 
Republic of Georgia 
Georgia 
Macharashvili, N., Kourbatova, E., Butsashvili, M., Tsertsvadze, T., McNutt, L.-
A., Leonard, M.K. 
2009 
International Journal of 
Infectious Diseases 
3.3 
Group B streptococcus colonization of pregnant women and 
their children observed on obstetric and neonatal wards of 
the University hospital in krakow, Poland 
Poland 
Strus, M., Pawlik, D., Brzychczy-Włoch, M., Gosiewski, T., Rytlewski, K., 
Lauterbach, R.,  
Heczko, P.B. 
2009 
Journal of Medical 
Microbiology 
2.7 
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Table 2: Recent literature from high impact journals 
  Title Authors Year Journal 
Journal 
 Impact 
Factor 
In
fe
ct
io
u
s 
D
is
ea
se
 J
o
u
rn
al
s 
Incidence of invasive group B streptococcal disease 
and pathogen genotype distribution in newborn babies 
in the Netherlands  Bekker V., Bijlsma M.W., van de Beek D., Kuijpers T.W., van der Ende A. 2014 Lancet ID 19.446 
Neonatal invasive haemophilus influenzae disease in  
England and Wales: Epidemiology, clinical 
characteristics, and outcome Collins S., Litt D.J., Flynn S., Ramsay M.E., Slack M.P.E., Ladhani S.N. 2015 
Clinical Infectious 
Diseases 9.416 
Incidence, etiology, and outcome of bacterial 
meningitis in infants aged <90 days in the United 
Kingdom and Republic of Ireland: Prospective, 
enhanced, national population-based surveillance 
Okike I.O., Johnson A.P., Henderson K.L., Blackburn R.M.,  
Muller-Pebody B., Ladhani S.N., Anthony M., Ninis N., Heath P.T. 2014 
Clinical Infectious 
Diseases 7.327 
            
P
ae
d
ia
tr
ic
 J
o
u
rn
al
s 
Early onset neonatal sepsis: The burden of group B 
streptococcal and E. coli diseases continues 
Stoll B., Hansen N.I., Sanchez P.J., Faix R.G., Poindexter B.B., Van Meurs K.P., Bizzaro M.J., Goldberg R.N., 
Frantz I.D., Hale E.C., Shankaran S., Kennedy K., Carlo W.A., Watterberg K.L., Bell E.F., Walsh M.C., 
Schibler K., Laptook A.R., Shane A.L., Schrag S.J., Das A., Higgins R.D. 2011 Pediatrics 5.297 
Group B streptococcus late-onset disease: 2003-2010 
Beradi A., Rossi C., Lugli L., Creti R., Reggiani M.L.B., Lanari M.,  
Memo L., Pedna M.F., Venturelli C., Perrone E., Ciccia M., Tridapalli E., Piepoli M., Contiero R., Ferrari F.  2013 Pediatrics 5.297 
Trends in candida central line-associated bloodstream 
 infections among NICUs, 1999-2009 Chitnis A.S., Magill S.S., Edwards J.R., Chiller T.M., Fridkin S.K., Lessa F.C. 2012 Pediatrics 5.297 
Changing epidemiology of bacteremia in infants aged 1 
week to 3 months Greenhow T.L., Hung Y-Y., Herz A.M 2012 Pediatrics 5.297 
Neonatal infections in China, Malaysia, Hong Kong 
and Thailand Al-Taiar A., Hammoud M.S., Cuiqing L., Lee J.K., Lui K.M., Nakwan N., Isaacs D. 2013 
Arch Dis Child: Fe Neonat 
Ed  3.861 
Seasonal variations in healthcare-associated infection 
 in neonates in Canada. Shah P.S., Yoon W., Kalapesi Z., Bassil K., Dunn M., Lee S.K. 2013 
Arch Dis Child: Fe Neonat 
Ed 3.861 
Multi-drug resistant gram negative bacilli causing early 
neonatal sepsis in India Viswanathan R., Singh A.K., Basu S., Chatterjee S., Sardar S., Isaacs D. 2012 
Arch Dis Child: Fe Neonat 
Ed 3.861 
Neonatal infections in England: The NeonIN 
surveillance network 
Vergnano S, Menson E, Kennea N, Embleton N, Russell AB, Watts T, Robinson MJ, 
 Collinson A, Heath PT 2011 
Archives of Disease in 
Childhood: 
 Fetal and Neonatal Ed. 3.861 
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1.C. Preliminary ist of potential reporting items 
Table 3. List of 133 potential reporting items derived from literature review 
Study 
Overview 
1. 
Study purpose 
a. Aim  
b. Contribution to existing research  
c. Primary outcomes  
d. Secondary outcomes  
2. 
Study design 
a. Study type or description of surveillance network (eg. cross-sectional, surveillance, case-control) 
b. Prospective vs. retrospective  
c. Data collection dates (day, month, year)  
d. Sample size calculations  
e. Inclusion criteria  
f. Exclusion criteria  
g. Case finding method  
(eg. systematic screening; active vs. passive 
surveillance) 
h. Method of randomisation  
i.  Ethical approval (name of board (s)/institution(s))  
j. Funding source(s)  
 k. Source of demographic data  
3. 
Recruitment 
a. Number of eligible subjects  
b. Number of subjects enrolled  
c. Number of excluded subjects  
d. Proportion of study subjects sampled  
e. Description of comparison groups (eg. size of groups; characteristics) 
f. Consent process  
 4. 
Statistical 
Methods 
a. Software used  
 b. Descriptive statistics methods  
 c. Modelling methods   
Setting 
5.  
Study site context 
a. Facility or community based  
b. Size of study site (catchment area or total population)  
c. Annual number of live births in study catchment area  
d. Neonatal mortality risk (per 1000 live births) in study area   
e. Stillbirth risk (per 1000 births) in study area  
f. Source of population denominator (eg. vital registration or census data) 
g. Climate or seasonal change, where relevant  
h. Healthcare staff (grade/qualification) looking after study patients 
(eg. Community Health Workers, clinical officers, 
medical officers, paediatricians) 
i. Training (study specific) conducted  
(eg. clinical algorithm to diagnose clinical possible 
severe bacterial infection) 
j.  Geographical location  
k. Endemic diseases (eg. malaria) 
l. HIV testing strategy  
m. Vaccination schedule  
n. Vaccination coverage  
o. Climate (eg. seasonal rainfall) 
6.  
Health facility 
(where applicable) 
a. Type of facility and which ward(s)/unit(s) included 
(eg. First level health facility, district, referral hospital; 
neonatal intensive care unit, paediatric ward) 
b. Criteria for admission (+/- ward)  
c. Annual admissions (+/- ward)  
d. Level of care available  
(eg. Level of respiratory support available: invasive 
ventilation, CPAP, oxygen, nil) 
e. Patients requiring ventilation, central lines, TPN and surgery, 
expressed as patient days (where relevant) 
(eg. total central-line days) 
f. Cot occupancy  
g. Infection control measures, availability of local guidelines, and 
adherence 
(eg. space between cots, hand washing) 
h. Availability and use of kangaroo mother care  
i. Size of health facility  
j. Annual number of live births at the health facility  
k. Annual number of admissions at the health facility  
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l. Outbreaks that occurred during the study  
m. Classification of ventilation requirement 
(eg. based on peak requirement vs. requirement at the 
time of data collection) 
Clinical  
Information 
7. 
Maternal 
demographic and 
clinical 
information 
a. Maternal age  
b. Parity  
c. Mode of delivery 
(eg. vaginal vs. elective caesarean vs. emergency 
caesarean) 
d. Complications during pregnancy / birth (eg. Prolonged Rupture Of Membranes) 
e. Recent maternal illness (eg. fever, UTI) 
f. Maternal co-morbidities (eg. Anaemia, malaria) 
g. Definitions used for maternal co-morbidities  
h. Antenatal screening for infections (eg. GBS, HIV, syphilis, Hep B) 
8.  
Newborn 
demographic and 
clinical 
information 
a. Sex  
b. Postnatal age range (and mean / median) of study participants  (in hours or days) 
c. Time between admission/birth and infection  
d. Gestational age range (and median) of study participants, including 
method of assessment and criteria used to define ‘preterm’ / ‘very 
preterm’ 
 
e. Birth weight range (and mean / median) of study participants, 
including criteria used to define ‘low birth weight’ / ‘very low birth 
weight’ 
 
f. Place of birth, defining terms such as 'inborn' and 'outborn'   
g. Newborn comorbidities  (eg. congenital malformations, HIV) 
h. Definitions used for newborn comorbidities  
i. Prognostic scores (eg. 10 minute Apgar score, CRIB score) 
9. 
Clinical 
assessment 
a. Physical examination and whether consistent  
b. Blood tests other than culture  (eg. FBC) 
c. Measurement of vital signs  (eg. pulse oximetry, temperature) 
d. Radiological investigations (eg. CXR) 
e. Method of documentation of case reports  (eg. standard data collection forms) 
10. 
Sampling 
strategy 
a. Indication for sample collection  (eg. clinically indicated vs. routine surveillance) 
b. Sample collection method  
(eg. whether aseptic technique used; clean catch vs. 
catheter for urine collection) 
c. Number of samples collected (from each subject)  
d. Volume of sample collected   
e. Methods for transfer/storage of clinical samples  
11. 
Treatment 
a. General case management  (eg. admission, IV fluid administration) 
b. Local empirical antimicrobial policy  
c. Antimicrobial point prevalence survey data  
12. 
Definitions of 
cases and 
denominators  
a. Infectious syndromes definitions (eg. sepsis, pneumonia, meningitis);  
b. Culture-proven infection definitions   
c.  HAI cases and outbreaks, definitions and duration of episode (eg. criteria for HABSI, CLABSI);  
d. ‘Early-onset’ and ‘late-onset’ infection definitions  
e. Denominator for incidence / mortality  (eg. patient days, live births, admissions) 
f. Stillbirth definitions, including subgroups 
(eg. intrapartum  (fresh) or Antepartum (macerated) 
stillbirth 
 g. Morbidity or long-term impairment definitions (eg. neurodisability) 
 
13. 
Antimicrobial use 
 
a. Prior administration of antimicrobial (or anti-fungal) agents in the 
newborn, including type and timing and whether serum testing was 
done  
b. Prior maternal use of antimicrobials (recent antenatal or 
intrapartum), including type and timing and whether for treatment or 
prophylaxis   
c. Indications / rationale for antimicrobial use (eg. empirical antibiotic policy) 
d. Number (+/- proportion) of study subjects who received 
antimicrobials, and type 
(eg. proportion who received gentamicin or 
meropenem) 
e. Route, dose (per kg per day) and durations of antimicrobial 
administration  (eg. oral, intramuscular, intravenous) 
Microbiology 
14.  
Context 
a. Location, description, and any accreditation of laboratory  
b. Samples taken for culture, including number, type and collection 
methods  
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c. Isolates defined as contaminants  
d. Quality control and validation 
(eg. whether any samples were externally validated; 
sensitivity or specificity of testing) 
15. 
Microbiological 
methods 
a. Process for dealing with polymicrobial cultures  
b. Conventional or molecular   
c. Broth or direct plating   
d. Gram staining or other method used   
e. Method(s) of pathogen identification, including culture/sub-culture 
methods, automated or manual  
(eg. biochemical testing, VITEK) 
f. Methods of DNA extraction, PCR and whole genome sequencing, 
including manufacturer of equipment used (where applicable)) 
(eg. quantitative, real-time, multiplex, 16s/18s, high 
throughput genome sequencing) 
g. Whether point of care tests were used and the type/brand  
16. 
Antimicrobial  
susceptibility 
testing 
a. Antimicrobial susceptibility testing methods  
b. Antimicrobial testing standards (eg. disc diffusion, e-test, MIC) 
c. Drugs tested  (eg. EUCAST/CLSI) 
d. Mechanisms of resistance tested for  
Whether point of care tests were used and the type/brand  
Results & 
Outcomes  
17. 
Microbiological 
results 
a. Number (+/- proportion(s)) of positive cultures  
b. Number (+/- proportion(s)) of isolates/pathogens (eg. group B strep., klebsiella sp.) 
c. Number (+/-proportion(s)) of isolates susceptible, intermediate or 
resistant to each antimicrobial (eg. PACCS, drug/bug combinations) 
d. Number (+/- proportion) of isolates classified as contaminants  
e. Number (+/- proportions(s)) of isolates that were gram positive vs. 
gram negatives 
 
f. Time between admission and positive culture  
18. 
Clinical results 
a. Number (+/- proportion) of babies meeting clinical case definition 
criteria 
(eg. number with pSBI, pneumonia, meningitis) 
b. Number (+/- proportion) of babies with culture-proven infection  
c. Number (+/- proportion(s)) of babies meeting criteria for hospital-
acquired infection 
(eg. HABSI, CLABSI) 
d. Incidence of infection cases (as per defined clinical and/or 
microbiological criteria) 
(eg. per 1000 patient days, live births, admissions) 
e. Number (+/- proportion(s)) and/or incidence of cases by risk factors (eg. by gestational age, postnatal age, birth weight) 
f. Trends in incidence risk  
19. 
Mortality and 
morbidity 
a. Overall mortality and/or case fatality risk, including timing (eg. at 7 and 28 days) 
b. Subgroup mortality or CFR analysis by pathogen (eg. GBS, E.Coli; resistant vs. sensitive) 
c. Subgroup mortality of CFR analysis by infection syndrome (eg. sepsis vs. meningitis) 
d. Subgroup mortality or CFR analysis by risk group (eg. by postnatal / gestational age, birth weight) 
e. Number (+/-proportion(s)) of stillbirths  (eg. of intrapartum vs antepartum stillbirths) 
 f. Morbidity outcomes (eg. long term neurological impairment) 
  g. Morality trends (eg. over months, years) 
 
20. 
Other 
a. Estimates of burden  
 b. Cost analysis   
 c. Sources of recruitment bias  
 d. Sources of information bias  
 e. Factors affecting generalizability of results  
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SECTION 2: Survey to rate potential reporting items 
2.A Countries of survey respondents 
 
 
 Table 4.   n % of total 
Africa 
   
Kenya  5 3.6% 
Nigeria 3 2.1% 
Ethiopia 2 1.4% 
Mozambique 1 0.7% 
Malawi 3 2.1% 
South Africa 4 2.9% 
Gambia 1 0.7% 
Egypt 1 0.7% 
Republic of Congo 1 0.7% 
Asia 
Sub Total 21 15.0% 
   
Cambodia 1 0.7% 
Bangladesh 2 1.4% 
India 22 15.7% 
Pakistan 2 1.4% 
Thailand 1 0.7% 
Hong Kong 1 0.7% 
Nepal 1 0.7% 
North America 
Sub Total 30 21.4% 
   
USA (see list of states) 27 19.3% 
Canada 1 0.7% 
Europe 
Sub Total 28 20.0% 
   
France 4 2.9% 
UK 29 20.7% 
Switzerland 4 2.9% 
Greece 4 2.9% 
Italy 3 2.1% 
Poland 1 0.7% 
Estonia 2 1.4% 
Netherlands 1 0.7% 
Middle East 
Sub Total 48 34.3% 
   
Qatar 1 0.7% 
UAE 1 0.7% 
Turkey 1 0.7% 
Oman 1 0.7% 
Latin America 
Sub Total 4 2.9% 
   
Peru 1 0.7% 
Venezuela 1 0.7% 
Guatemala 1 0.7% 
Brazil 2 1.4% 
Argentina 1 0.7% 
 
 
Sub Total 5 4.3% 
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Australasia 
Australia 3 2.1% 
New Zealand 1 0.7% 
 
 
 
 
(USA states) 
Sub Total 4 2.9% 
   
 
 
Washington DC 
 
 
4 
 
 
2.9% 
Washington State 1 0.7% 
Massachusetts 4 2.9% 
New York 1 0.7% 
Indiana 1 0.7% 
Maryland 2 1.4% 
Georgia (US) 2 1.4% 
North Carolina 3 2.1% 
New Jersey 1 0.7% 
Ohio 2 1.4% 
Texas 2 1.4% 
Missouri 1 0.7% 
Philadelphia 1 0.7% 
Colorado 1 0.7% 
California 1 0.7% 
  Sub Total 27 19.3% 
    
 Number with country data 141  
 Number without country data 6  
  Total respondents 147   
  Total countries 37   
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2.B. Survey Tool 
Bristol Online Surveys: www.onlinesurveys.ac.uk 
 
 
 
 
 
 
 
 












1"
O
nline&Survey&Results&
RESU
LTS:&
H
ow
&im
portant&is&it&to&report&the&
follow
ing&item
s&in&neonatal&
infec>
on&studies?&
1.&SeC
ng:&Study&Site&
1.1.&Facility&or&com
m
unity&based&study"
4&
3%
&
37&
26%
&
103&
71%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
24
2"
1.2.&Size&of&study&site&catchm
ent&area&or&
total&popula>
on"
15&
10%
&
66&
46%
&
62&
43%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
1.3.&A
nnual&num
ber&of&live&births&in&study&
catchm
ent&area"
15&
10%
&
65&
45%
&
63&
44%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
1.4.&N
eonatal&m
ortality&rate&in&study&area"
15&
10%
&
57&
40%
&
71&
49%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
1.5.&Preterm
&birth&rate&in&study&area&"
27&
19%
&
60&
42%
&
53&
38%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
25
3"
1.6.&S>
llbirth&rate&in&study&area"
9&
7%
&
53&
37%
&
50&
35%
&
30&
21%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
1.7.&Source&of&popula>
on&denom
inator&&
eg."source"of"vital"registra.on"or"survey"data""
17&
12%
&
45&
31%
&
82&
56%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
1.8.&Clim
ate&or&seasonal&change&during&
study,&w
here&relevant"
11&
8%
&
77&
53%
&
47&
32%
&
10&
7%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
1.9.&Type&/&grade&and&num
ber&of&healthcare&
staﬀ
&looking&aY
er&study&pa>
ents&
eg."com
m
unity"health"w
orkers,"neonatal"nurses,"paediatricians;"nurse"to"pa.ent"ra.o""
53&
36%
&
51&
35%
&
40&
28%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
26
4"
1.10.&Study&speciﬁc&training&conducted&&
eg."clinical"algorithm
"to"diagnose"possible"bacterial"infec.ons""
34&
23%
&
49&
34%
&
61&
42%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
1.11.&O
bstetric&care&provided&
eg."trained"or"untrained"birth"aD
endant;"obstetric"prac.ces,"infec.on"control"
prac.ces"in"the"delivery"room
,"availability"of"antenatal"steroids""
2&
1%
&
26&
18%
&
61&
43%
&
54&
38%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
2.&SeC
ng:&H
ealth&Facility&
2.1.&Type&of&facility&and&w
hich&w
ard(s)/
unit(s)&included&
eg."ﬁrst"level"health"centres,"district"hospitals,"referral"hospital;"neonatal"intensive"care"
unit,"paediatric"w
ard;"private,"public""
6&
4%
&
54&
37%
&
85&
59%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
27
5"
2.2.&Criteria&for&adm
ission&to&the&health&
facility&(+/^&w
ard)"
4&
3%
&
22&
15%
&53&
37%
&
66&
45%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
2.3.&A
nnual&num
ber&of&adm
issions&to&
health&facility&(+/^&w
ard)"
27&
19%
&
70&
48%
&
47&
32%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
2.4.&Level&of&neonatal&care&available&
eg."level"of"respiratory"support"oﬀered:"m
echanical"ven.la.on,"con.nuous"
posi.ve"airw
ay"pressure,"oxygen,"none""
8&
6%
&
57&
39%
&
80&
55%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
2.5.&N
um
ber&of&pa>
ents&requiring&
interven>
ons&
eg."ven.la.on,"central"lines,"TPN
"and"surgery,"expressed"as"pa.ent"days"
27&
18%
&
61&
42%
&
56&
39%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
28
6"
2.6.&A
verage&cot&occupancy&rates"
4&
3%
&
61&
42%
&
51&
35%
& 29&
20%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
2.7.&Infec>
on&control&m
easures&and&
adherence&(including&the&delivery&room
)&
eg."space"betw
een"cots,"audit"data"on"hand"w
ashing""
27&
19%
&55&
38%
&
61&
43%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
2.8.&A
vailability&and&use&of&kangaroo&
m
other&care"
7&
5%
&
53&
37%
&
54&
37%
&
31&
21%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
3.&Clinical&Inform
a>
on:&M
aternal&
29
7"
3.1.&M
aternal&age"
11&
8%
&
59&
41%
&
37&
26%
&
36&
25%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
3.2.&Parity"
12&
8%
&
60&
42%
&
41&
28%
& 32&
22%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
3.3.&M
ode&of&delivery&
eg."vaginal"vs."elec.ve"caesarean"vs."em
ergency"caesarean""
10&
7%
&
51&
35%
&
83&
57%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
3.4.&Com
plica>
ons&during&&
pregnancy&or&delivery&
eg."prolonged"or"preterm
"rupture"of"m
em
branes""
20&
14%
&
45&
31%
&
80&
55%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
30
8"
3.5.&Recent&m
aternal&illness&
eg."fever,"urinary"tract"infec.on""
17&
12%
&
60&
41%
&
68&
47%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
3.6.&List&of&m
aternal&com
orbidi>
es&
eg."anaem
ia,"m
alaria""
2&
1%
&
42&
29%
&
63&
44%
&
38&
26%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
3.7.&A
ntenatal&screening&for&infec>
ons&
eg."G
BS,"H
IV,"syphilis,"H
ep"B""
27&
19%
&53&
36%
&
65&
45%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.&Clinical&Inform
a>
on:&N
ew
born&
31
9"
4.1.&Sex"
18&
13%
&
39&
27%
&
87&
60%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.2.&Postnatal&age&range&&
(and&m
ean&/&m
edian)&of&study&par>
cipants&
(in&hours&or&days)"
2&
1%
&
25&
18%
&
115&
81%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.3.&Tim
ing&of&infec>
on,&including&
propor>
on&of&cases&occurring&on&the&ﬁrst&
day&of&life&that&w
ere&captured"
2&
1%
&
21&
15%
&
121&
84%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.4.&G
esta>
onal&age&range&&
(and&m
edian)&of&study&par>
cipants,&&
including&m
ethod&of&assessm
ent"
3&
2%
&
35&
24%
&
107&
74%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
32
10"
4.5.&Birth&w
eight&range&&
(and&m
ean&/&m
edian)&of&study&par>
cipants"
1&
1%
&
32&
22%
&
111&
77%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.6.&Place&of&birth&
eg."facility"vs."hom
e"births;"'inborn'"or"'outborn'""
2&
1%
&
10&
7%
&
42&
29%
&
91&
63%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.7.&List&of&com
orbidi>
es&
eg."congenital"m
alform
a.ons,"H
IV""
16&
11%
&
59&
41%
&
69&
48%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.8.&Prognos>
c&scores&
eg."10"m
inute"A
pgar"score,"CRIB"score""
3&
2%
&
49&
34%
&
59&
41%
&
33&
23%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
33
11"
4.9.&M
ethods&of&clinical&assessm
ent&including&
exam
ina>
on&perform
ed,&vital&signs,&blood&tests&
(other&than&culture)&and&radiological&inves>
ga>
ons&
eg."O
2"sats,"FBC,"inﬂam
m
atory"m
arkers,"chest"radiograph"
13&
9%
&
53&
37%
&
79&
54%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.10.&Suppor>
ve&care&available&
eg."intravenous"ﬂuid"adm
inistra.on,"nasogastric"feeds,"phototherapy""
19&
13%
&75&
52%
&
51&
35%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
4.11.&Follow
&up&period&
eg."to"discharge,"to"28"days""
2&
1%
&
46&
32%
&
95&
67%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
5.&Clinical&Inform
a>
on:&
A
n>
m
icrobial&use&
34
12"
5.1.&Prior&adm
inistra>
on&of&an>
m
icrobials&
to&the&new
born,&including&type&and&>
m
ing"
7&
5%
&
38&
26%
&
100&
69%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
5.2.&U
se&of&m
aternal&intrapartum
&
an>
bio>
c&prophylaxis""
7&
5%
&
45&
31%
&
93&
64%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
5.3.&Indica>
ons&/&ra>
onale&for&
an>
m
icrobial&use&
eg."em
pirical"an.bio.c"policy"or"criteria"for"star.ng"an.bio.cs""
22&
15%
&
48&
33%
&
75&
52%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
5.4.&N
um
ber&(+/^&propor>
on)&of&study&subjects&
w
ho&received&an>
m
icrobials,&and&type&used&
eg."propor.on"w
ho"received"gentam
icin"or"m
eropenem
""
4&
3%
&
51&
35%
&
90&
62%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
35
13"
5.5.&Route,&dose&and&dura>
on&of&
an>
m
icrobial&adm
inistra>
on&
eg."oral,"intram
uscular,"intravenous""
2&
1%
&
18&
13%
&
48&
33%
&
77&
53%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
6.&M
icrobiology:&Context&
6.1.&Loca>
on,&descrip>
on,&and&any&
accredita>
on&of&laboratory"
5&
4%
&
48&
33%
&
61&
42%
&
31&
21%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
6.2.&Sam
ples&taken&for&culture,&including&
type&and&collec>
on&m
ethods&
eg."blood"or"CSF;"num
ber"and"volum
e"taken"from
"each"baby""
11&
7%
&
43&
30%
&
90&
62%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
36
14"
6.3.&Reason&for&sam
ple&collec>
on&
eg."rou.ne"surveillance,"study"requirem
ent,"clinical"indica.on""
25&
18%
&
62&
43%
&
55&
38%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
6.4.&Tim
ing&of&sam
ple&collec>
on&in&rela>
on&
to&an>
m
icrobial&adm
inistra>
on&
eg."sam
ples"taken"before"or"a^
er"star.ng"an.bio.cs""
10&
7%
&
48&
34%
&
84&
59%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
6.5.&Q
uality&control&and&valida>
on&
eg."w
hether"sam
ples"w
ere"externally"validated;"sensi.vity"or"speciﬁcity"of"tes.ng""
2&
1%
&
24&
17%
&58&
40%
&
61&
42%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
7.&M
icrobiology:&Culture&M
ethods&
37
15"
7.1.&W
hether&conven>
onal&or&m
olecular&
m
ethods&used""
24&
16%
&
46&
32%
&
75&
52%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
7.2.&Culture&incuba>
on&m
ethods&
eg."BACTEC""
2&
1%
&
25&
17%
&
59&
41%
&
59&
41%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
7.3.&G
ram
&staining&or&other&m
ethod&
used&for&early&diagnosis"
4&
3%
&
38&
26%
&
59&
41%
&
44&
30%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
7.4.&M
ethod(s)&of&pathogen&iden>
ﬁca>
on,&
including&culture/sub^culture&m
ethods&
eg."autom
ated"or"m
anual,"biochem
ical"tes.ng,"VITEK""
21&
14%
&
55&
38%
&
68&
47%
&
U
nnecessary"
Som
e.m
es"useful"
Im
portant"for"m
ost"
studies"
Essen.al"for"all"
studies"
38
16"
8.&M
icrobiology:&A
n>
m
icrobial&
Suscep>
bility&Tes>
ng&
8.1.&A
n>
m
icrobial&suscep>
bility&tes>
ng&m
ethods,&
including&w
hether&autom
ated&or&m
anual&
eg."disc"diﬀ
usion,"e`test,"m
inim
um
"inhibitory"concentra.on"(M
IC)""
23&
16%
&
56&
38%
&
65&
45%
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